OTCMKTS:SHTDY

Sinopharm Group News Headlines

$15.32
+1.14 (+8.04 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.18
Now: $15.32
$15.35
50-Day Range
$11.25
MA: $12.14
$14.18
52-Week Range
$10.20
Now: $15.32
$15.35
Volume38,560 shs
Average Volume52,224 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Sinopharm Group (OTCMKTS SHTDY) News Headlines Today

SourceHeadline
Doubts overshadow China’s pledge to vaccinate developing countriesDoubts overshadow China’s pledge to vaccinate developing countries
finance.yahoo.com - March 24 at 8:48 AM
Doubts overshadow Beijing’s pledge to vaccinate the developing worldDoubts overshadow Beijing’s pledge to vaccinate the developing world
finance.yahoo.com - March 23 at 10:47 PM
UAE offers third shot of Chinese vaccine in some casesUAE offers third shot of Chinese vaccine in some cases
finance.yahoo.com - March 17 at 2:54 PM
Early Adopter U.A.E. Starts Giving Third Dose of Sinopharm Vaccine Amid Efficacy ConcernsEarly Adopter U.A.E. Starts Giving Third Dose of Sinopharm Vaccine Amid Efficacy Concerns
wsj.com - March 13 at 6:54 PM
U.A.E. Giving Third Shot of Sinopharm Vaccine to SomeU.A.E. Giving Third Shot of Sinopharm Vaccine to Some
wsj.com - March 12 at 9:59 PM
Palace studying if Duterte can receive SinopharmPalace studying if Duterte can receive Sinopharm
msn.com - March 1 at 2:02 PM
Hungarians receive Chinese Covid vaccine as Orban breaks with EU strategyHungarians receive Chinese Covid vaccine as Orban breaks with EU strategy
finance.yahoo.com - March 1 at 9:01 AM
Half of Israelis Vaccinated; NYC School Spread Low: Virus UpdateHalf of Israelis Vaccinated; NYC School Spread Low: Virus Update
msn.com - February 28 at 12:11 AM
Israel Milestone, Moderna Changes Medical Officer: Virus UpdateIsrael Milestone, Moderna Changes Medical Officer: Virus Update
bloomberg.com - February 25 at 3:15 PM
South Africa says J&J, Pfizer, Moderna vaccines those for immediate useSouth Africa says J&J, Pfizer, Moderna vaccines those for 'immediate use'
reuters.com - February 24 at 12:16 AM
Argentina approves Sinopharm COVID-19 vaccine for emergency useArgentina approves Sinopharm COVID-19 vaccine for emergency use
finance.yahoo.com - February 21 at 6:49 PM
New Covid strain: Sinopharm vaccine effective against South African variantNew Covid strain: Sinopharm vaccine effective against South African variant
msn.com - February 3 at 5:42 AM
Sinopharms COVID-19 vaccine remained active against S.Africa variant, effect reduced - lab studySinopharm's COVID-19 vaccine remained active against S.Africa variant, effect reduced - lab study
reuters.com - February 3 at 5:42 AM
Peru Volunteer Who Took Part In Vaccine Trial Reportedly Dies Of COVID-19 PneumoniaPeru Volunteer Who Took Part In Vaccine Trial Reportedly Dies Of COVID-19 Pneumonia
msn.com - January 27 at 10:17 AM
Covid-19 Vaccines and How They WorkCovid-19 Vaccines and How They Work
wsj.com - January 27 at 10:17 AM
Peru volunteer who received placebo in Sinopharm vaccine trial dies of COVID-19 pneumonia, university saysPeru volunteer who received placebo in Sinopharm vaccine trial dies of COVID-19 pneumonia, university says
msn.com - January 27 at 5:17 AM
Peru volunteer in Sinopharm vaccine trial dies of COVID-19 pneumonia, university saysPeru volunteer in Sinopharm vaccine trial dies of COVID-19 pneumonia, university says
finance.yahoo.com - January 26 at 5:32 PM
Coronavirus: China National Biotec Group vouches for its vaccine against mutant strains spreading overseasCoronavirus: China National Biotec Group vouches for its vaccine against mutant strains spreading overseas
msn.com - January 26 at 12:31 PM
Peru to pay $26 mln for first shipment of Sinopharm vaccine -ministerPeru to pay $26 mln for first shipment of Sinopharm vaccine -minister
finance.yahoo.com - January 12 at 2:36 PM
Chinese, UK COVID vaccines show promiseChinese, UK COVID vaccines show promise
msn.com - December 31 at 6:33 PM
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.